Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded by StockNews.com to Strong-Buy Rating

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Stock Down 3.2 %

AUPH opened at $8.07 on Thursday. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The firm has a 50 day moving average price of $8.74 and a 200-day moving average price of $7.22. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $10.67. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -53.80 and a beta of 1.24.

Insider Buying and Selling

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the transaction, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. This represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. CWM LLC lifted its position in Aurinia Pharmaceuticals by 247.7% during the third quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 8,180 shares during the last quarter. FMR LLC lifted its position in Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 3,919 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in Aurinia Pharmaceuticals during the second quarter valued at $84,000. China Universal Asset Management Co. Ltd. lifted its position in Aurinia Pharmaceuticals by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 10,700 shares during the last quarter. Finally, PFG Investments LLC lifted its position in Aurinia Pharmaceuticals by 37.9% during the second quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 7,900 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.